Pasar al contenido principal
Optimising effectiveness img
Apertura:
20 de Febrero, 2022
Cierre:
20 de Abril, 2022
Hora de Cierre:
11:59 PM

Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

Tipo

Investigación

Área de Conocimiento

Escuela de Medicina y Ciencias de la Salud

País

Aplica para Diferentes Paises

Ente financiador

Comisión Europea

Monto a subvencionar

EUR 35 000 000

Área/Tema (específico)

Biomarkers/ Technology/ Drug prescription

 

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:

Diagnostics industries move towards market approval for companion diagnostics.
Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.

Low- and middle-income countries

 

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:

Diagnostics industries move towards market approval for companion diagnostics.
Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.

Low- and middle-income countries